Filtered By:
Source: Cancers

This page shows you your search results in order of date.

Order by Relevance | Date

Total 223 results found since Jan 2013.

Cancers, Vol. 15, Pages 4572: Tumor-Promoting Role of GNA14 in Colon Cancer Development
In this study, we examined the effect of GNA14 on CRC through genetic approaches in vitro and in vivo. We found that GNA14 knockdown by small interfering RNA (siRNA) inhibited the proliferation of CRC cells SW403 and HT29. Gna14 knockout mice developed normally without obvious abnormalities. However, the number of polyps in the small intestine was significantly reduced in Gna14 knockout mice compared to control mice after mating with ApcMin mice, a representative CRC mouse model. In particular, deletion of the Gna14 inhibited polyp growth, especially in the distal end of the small intestine. Histological examination showed...
Source: Cancers - September 15, 2023 Category: Cancer & Oncology Authors: Rahui Park Seungmin Lee Hyunjung Chin Anh Thai-Quynh Nguyen Daekee Lee Tags: Article Source Type: research

Cancers, Vol. 15, Pages 4467: Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in A Colorectal Cancer Model
In this study, we combined DMR with immune checkpoint inhibitors (ICIs) in a model of colon adenocarcinoma. In vitro, we observed that MR increased the expression of MHC-I and PD-L1 in both mouse and human colorectal cancer cells. We also saw an increase in the gene expression of STING, a known inducer of type I interferon signaling. Inhibition of the cGAS–STING pathway, pharmacologically or with siRNA, blunted the increase in MHC-I and PD-L1 surface and gene expression following MR. This indicated that the cGAS–STING pathway, and interferon in general, played a role in the immune response to MR...
Source: Cancers - September 7, 2023 Category: Cancer & Oncology Authors: Lauren C. Morehead Sarita Garg Katherine F. Wallis Camila C. Simoes Eric R. Siegel Alan J. Tackett Isabelle R. Miousse Tags: Article Source Type: research

Cancers, Vol. 15, Pages 4189: Oncogenic Targets Regulated by Tumor-Suppressive miR-30c-1-3p and miR-30c-2-3p: TRIP13 Facilitates Cancer Cell Aggressiveness in Breast Cancer
kajo Naohiko Seki Accumulating evidence suggests that the miR-30 family act as critical players (tumor-suppressor or oncogenic) in a wide range of human cancers. Analysis of microRNA (miRNA) expression signatures and The Cancer Genome Atlas (TCGA) database revealed that that two passenger strand miRNAs, miR-30c-1-3p and miR-30c-2-3p, were downregulated in cancer tissues, and their low expression was closely associated with worse prognosis in patients with BrCa. Functional assays showed that miR-30c-1-3p and miR-30c-2-3p overexpression significantly inhibited cancer cell aggressiveness, suggesting these two miRNAs act...
Source: Cancers - August 21, 2023 Category: Cancer & Oncology Authors: Reiko Mitsueda Hiroko Toda Yoshiaki Shinden Kosuke Fukuda Ryutaro Yasudome Mayuko Kato Naoko Kikkawa Takao Ohtsuka Akihiro Nakajo Naohiko Seki Tags: Article Source Type: research

Cancers, Vol. 15, Pages 3810: Characterization of DoTc2 4510 & mdash;Identifying HPV16 Presence in a Cervical Carcinoma Cell Line Previously Considered to Be HPV-Negative
Cancers, Vol. 15, Pages 3810: Characterization of DoTc2 4510—Identifying HPV16 Presence in a Cervical Carcinoma Cell Line Previously Considered to Be HPV-Negative Cancers doi: 10.3390/cancers15153810 Authors: Nika Vučković Karin Hoppe-Seyler Angelika B. Riemer Cervical cancer is the fourth leading cause of cancer deaths in women, with over 340,000 women dying from this disease in 2020. Almost all cases have an underlying persistent infection with an oncogenic high-risk type of human papillomavirus (HPV), mainly HPV16. While cervical squamous cell carcinoma is hardly ever HPV-negative, a small subset...
Source: Cancers - July 27, 2023 Category: Cancer & Oncology Authors: Nika Vu čković Karin Hoppe-Seyler Angelika B. Riemer Tags: Article Source Type: research

Cancers, Vol. 15, Pages 3461: PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
In this study, we investigated the role of PRMT-1 and p120-catenin in mediating Osimertinib resistance (OR) through EMT. These studies found upregulation of gene and protein expression of PRMT-1, p120-catenin and Kaiso factor. Knockdown of p120-catenin using siRNA increased OR efficacy by 45% as compared to cells treated with mock siRNA and OR. After 24 h of transfection, the percentage wound closure in cells transfected with p120-catenin siRNA was 26.2%. However, in mock siRNA-treated cells the wound closure was 7.4%, showing its involvement in EMT. We also found high levels of p120-catenin expressed in 30% of smokers as ...
Source: Cancers - July 1, 2023 Category: Cancer & Oncology Authors: Kavya Sri Racherla Katrina Dovalovsky Meet Patel Emma Harper Jacob Barnard SM Nasifuzzaman Mason Smith Riya Sikand Eva Drinka Neelu Puri Tags: Article Source Type: research

Cancers, Vol. 15, Pages 3432: Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1
In this study, using chromatin immunoprecipitation (ChIP) assay and siRNA, we demonstrate that vitamin D/VDR regulates PD-L1 expression in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells. We have examined whether a VDR antagonist, MeTC7, can inhibit PD-L1. To ensure that MeTC7 inhibits VDR/PD-L1 without off-target effects, we examined competitive inhibition of VDR by MeTC7, utilizing ligand-dependent dimerization of VDR-RXR, RXR-RXR, and VDR-coactivators in a mammalian 2-hybrid (M2H) assay. MeTC7 inhibits VDR selectively, suppresses PD-L1 expression sparing PD-L2, and inhibits the cell viability, clon...
Source: Cancers - June 30, 2023 Category: Cancer & Oncology Authors: Negar Khazan Emily R. Quarato Niloy A. Singh Cameron W. A. Snyder Taylor Moore John P. Miller Masato Yasui Yuki Teramoto Takuro Goto Sabeeha Reshi Jennifer Hong Naixin Zhang Diya Pandey Priyanka Srivastava Alexandra Morell Hiroki Kawano Yuko Kawano Thomas Tags: Article Source Type: research

Cancers, Vol. 15, Pages 2901: Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stromal Cells as an Efficient Nanocarrier to Deliver siRNA or Drug to Pancreatic Cancer Cells
In conclusion, the use of UC-MSC-derived EVs as a drug delivery system for siRNAs or drugs could be a promising approach for the targeted treatment of PDAC.
Source: Cancers - May 24, 2023 Category: Cancer & Oncology Authors: Florian Draguet Nathan Dubois Cyril Bouland Karlien Pieters Dominique Bron Nathalie Meuleman Basile Stamatopoulos Laurence Lagneaux Tags: Article Source Type: research

Cancers, Vol. 15, Pages 2496: Protein Levels of Anti-Apoptotic Mcl-1 and the Deubiquitinase USP9x Are Cooperatively Upregulated during Prostate Cancer Progression and Limit Response of Prostate Cancer Cells to Radiotherapy
Conclusion: Posttranslational regulation of protein stability was often responsible for high protein levels of Mcl-1. Moreover, we demonstrated that deubiquitinase USP9x as a factor regulating Mcl-1 levels in prostate cancer cells, thus limiting cytotoxic response to radiotherapy.
Source: Cancers - April 26, 2023 Category: Cancer & Oncology Authors: Sophia A. Hogh-Binder Diana Klein Frederik Wolfsperger Stephan M. Huber J örg Hennenlotter Arnulf Stenzl Justine Rudner Tags: Article Source Type: research

Cancers, Vol. 15, Pages 2317: Myo-Inositol Reverses TGF- & beta;1-Induced EMT in MCF-10A Non-Tumorigenic Breast Cells
Cancers, Vol. 15, Pages 2317: Myo-Inositol Reverses TGF-β1-Induced EMT in MCF-10A Non-Tumorigenic Breast Cells Cancers doi: 10.3390/cancers15082317 Authors: Noemi Monti Simona Dinicola Alessandro Querqui Gianmarco Fabrizi Valeria Fedeli Luisa Gesualdi Angela Catizone Vittorio Unfer Mariano Bizzarri Epithelial-Mesenchymal Transition (EMT), triggered by external and internal cues in several physiological and pathological conditions, elicits the transformation of epithelial cells into a mesenchymal-like phenotype. During EMT, epithelial cells lose cell-to-cell contact and acquire unusual motil...
Source: Cancers - April 15, 2023 Category: Cancer & Oncology Authors: Noemi Monti Simona Dinicola Alessandro Querqui Gianmarco Fabrizi Valeria Fedeli Luisa Gesualdi Angela Catizone Vittorio Unfer Mariano Bizzarri Tags: Article Source Type: research

Cancers, Vol. 15, Pages 2189: THY1 (CD90) Maintains the Adherens Junctions in Nasopharyngeal Carcinoma via Inhibition of SRC Activation
In this study we show that tumor invasion could be suppressed by THY1 via adherens junction formation in a few NPC cell lines, and knockdown of THY1 would disrupt this cell-cell adhesion phenotype. Mechanistically, the activity of the SRC family kinase (SFK) member, SRC, and canonical Wnt signaling were dramatically reduced when THY1 was constitutively expressed. Previous studies by others have found that high levels of SRC activity in NPCs are associated with EMT and a poor prognosis. We hypothesized that THY1 can suppress tumor invasion in NPC via inhibition of SRC. By gene silencing of SRC, we found that the in vitro NP...
Source: Cancers - April 6, 2023 Category: Cancer & Oncology Authors: Luo Chen Wai Yin Chau Hei Tung Yuen Xiao Han Liu Robert Zhong Qi Maria Li Lung Hong Lok Lung Tags: Article Source Type: research

Cancers, Vol. 15, Pages 2005: CDK4/6 Inhibition Induces Senescence and Enhances Radiation Response by Disabling DNA Damage Repair in Oral Cavity Squamous Cell Carcinoma
Conclusion: Targeting CDK4/6 can lead to improved efficacy when combined with radiation in OCSCC by inducing senescence and inhibiting DNA damage repair.
Source: Cancers - March 28, 2023 Category: Cancer & Oncology Authors: Nitisha Shrivastava Claudia Gutierrez Chavez Daniel Li Vikas Mehta Carlos Thomas Cory D. Fulcher Nicole Kawachi Danielle M. Bottalico Michael B. Prystowsky Indranil Basu Chandan Guha Thomas J. Ow Tags: Article Source Type: research

Cancers, Vol. 15, Pages 1397: PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
nno Nicola Maurea Cancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein involved in metabolism of low-density lipoprotein (LDL) cholesterol. PCSK9 blocking agents are clinically available and involve monoclonal antibodies, and SiRNA reduces LDL levels in high-risk patients and atherosclerotic cardiovascular disease events in multiple patient cohorts. Moreover, PCSK9 induces perip...
Source: Cancers - February 22, 2023 Category: Cancer & Oncology Authors: Vincenzo Quagliariello Irma Bisceglia Massimiliano Berretta Martina Iovine Maria Laura Canale Carlo Maurea Vienna Giordano Andrea Paccone Alessandro Inno Nicola Maurea Tags: Review Source Type: research

Cancers, Vol. 15, Pages 1158: Unique Metabolic Contexts Sensitize Cancer Cells and Discriminate between Glycolytic Tumor Types
nning Cancer cells utilize variable metabolic programs in order to maintain homeostasis in response to environmental challenges. To interrogate cancer cell reliance on glycolytic programs under different nutrient availabilities, we analyzed a gene panel containing all glycolytic genes as well as pathways associated with glycolysis. Using this gene panel, we analyzed the impact of an siRNA library on cellular viability in cells containing only glucose or only pyruvate as the major bioenergetic nutrient source. From these panels, we aimed to identify genes that elicited conserved and glycolysis-dependent changes in cellu...
Source: Cancers - February 11, 2023 Category: Cancer & Oncology Authors: Jonathan A. Chacon-Barahona Jeffrey P. MacKeigan Nathan J. Lanning Tags: Article Source Type: research

Cancers, Vol. 15, Pages 834: Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis
Johannes F. Fahrmann The nuclear factor erythroid 2-related factor 2 (NRF2) pathway is frequently activated in various cancer types. Aberrant activation of NRF2 in cancer is attributed to gain-of-function mutations in the NRF2-encoding gene NFE2L2 or a loss of function of its suppressor, Kelch-like ECH-associated protein 1 (KEAP1). NRF2 activation exerts pro-tumoral effects in part by altering cancer cell metabolism. Previously, we reported a novel mechanism of NRF2 tumoral immune suppression through the selective upregulation of the tryptophan-metabolizing enzyme kynureninase (KYNU) in lung adenocarcinoma. In the cu...
Source: Cancers - January 29, 2023 Category: Cancer & Oncology Authors: Ricardo A. Le ón-Letelier Ali H. Abdel Sater Yihui Chen Soyoung Park Ranran Wu Ehsan Irajizad Jennifer B. Dennison Hiroyuki Katayama Jody V. Vykoukal Samir Hanash Edwin J. Ostrin Johannes F. Fahrmann Tags: Article Source Type: research

Cancers, Vol. 15, Pages 628: Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)
Conclusions: ITGA2 emerged as a new prognostic factor, highlighting the relevance of stroma mechanical properties as potential therapeutic targets to counteract gemcitabine resistance in PDAC.
Source: Cancers - January 19, 2023 Category: Cancer & Oncology Authors: Alessandro Gregori Cecilia Bergonzini Mjriam Capula Giulia Mantini Fatemeh Khojasteh-Leylakoohi Annalisa Comandatore Ghazaleh Khalili-Tanha Alireza Khooei Luca Morelli Amir Avan Erik H. Danen Thomas Schmidt Elisa Giovannetti Tags: Article Source Type: research